Response-Adapted and Time-Limited Venetoclax, Umbralisib, and Ublituximab for Relapsed/Refractory CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Response-Adapted, Time-Limited Venetoclax, Umbralisib and Ublituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia
Blood Adv 2023 Oct 23;[EPub Ahead of Print], BT Hill, S Ma, CS Zent, AM Baran, DS Wallace, AS Advani, AM Winter, JN Winter, LI Gordon, R Karmali, JL Liesveld, DA Mulford, C Rowland, A Bui, P Sportelli, HP Miskin, MS Weiss, JW Friedberg, PM BarrFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.